A comparative study of postpartum hemorrhage severity in mothers with and without methylergometrine administration in normal labor
DOI: https://doi.org/10.56922/mchc.v4i11.2528
Methylergometrine Normal Vaginal Delivery Postpartum Hemorrhage Uterotonic Agents
Abstract
Background: Postpartum hemorrhage is a major cause of maternal morbidity and mortality, particularly in vaginal delivery, with uterine atony as the most common etiology. Therefore, the administration of uterotonic agents during the third stage of labor plays an important role in preventing postpartum hemorrhage. Methylergometrine is still widely used; however, data regarding its effect on the severity of postpartum hemorrhage in Indonesia remain limited.
Purpose: To compare the severity of postpartum hemorrhage among women with normal vaginal delivery who received and did not receive methylergometrine at RSUD Dr. Moewardi Surakarta.
Method: This study was an observational analytic study with a retrospective cohort design using secondary data from medical records. A total of 92 women with normal vaginal delivery who experienced primary postpartum hemorrhage during the period 2022–2024 were included and divided into groups receiving and not receiving methylergometrine. The severity of postpartum hemorrhage was classified into mild–moderate and severe. Data were analyzed using univariate and bivariate analyses with the Fisher’s exact test at a significance level of p < 0.05.
Results: All women who received methylergometrine experienced mild–moderate postpartum hemorrhage, whereas 9.5% of severe postpartum hemorrhage cases were found in the group that did not receive methylergometrine. There was a significant association between methylergometrine administration and the severity of postpartum hemorrhage (p = 0.026), with an odds ratio of 0.905 (95% CI: 0.820–0.998).
Conclusion: Methylergometrine administration was significantly associated with a reduced severity of postpartum hemorrhage in women with normal vaginal delivery.
Downloads
References
Alam, A., Shyam, P., & Goswami, S. (2017). A comparative study of efficacy of oxytocin, methylergometrine and misoprostol in prevention of post-partum haemorrhage. Int J Reprod Contracept Obstet Gynecol, 6(5), 1960-4.
Barth, E., Klapdor, R., Brodowski, L., Hillemanns, P., von Kaisenberg, C., & Dütemeyer, V. (2025). Postpartum hemorrhage: risk factors for severe blood loss, surgical intervention and peripartum hysterectomy. Archives of Gynecology and Obstetrics, 312(1), 167-176.
Cecilia, M., Vijayaselvi, R., Bansal, R., Lakshmi, L., & Jose, R. (2018). Ten units intravenous oxytocin over 2–4 h is as effective as 30 units over 8–12 h in preventing postpartum hemorrhage after cesarean section: A randomized controlled trial. Indian Journal of Pharmacology, 50(5), 279-283.
Central Java Provincial Health Office. (2023). Profil Kesehatan Jawa Tengah Tahun 2022. Retrieved from: www.dinkesjatengprov.go.id
Dhore, M., Munshi, A., Gaitonde, M., Chaudhary, N., Gala, M., Muchhala, S., & Kotak, B. (2025). Methylergometrine role in clinical practice. Indian Journal of Obstetrics and Gynecology Research, 12(3), 392-399.
Fanning, R. A., Sheehan, F., Leyden, C., Duffy, N., Iglesias-Martinez, L. F., Carey, M. F., & O’Connor, J. J. (2017). A role for adrenergic receptors in the uterotonic effects of ergometrine in isolated human term nonlaboring myometrium. Anesthesia & Analgesia, 124(5), 1581-1588.
Gallos, I. D., Papadopoulou, A., Man, R., Athanasopoulos, N., Tobias, A., Price, M. J., & Coomarasamy, A. (2018). Uterotonic agents for preventing postpartum haemorrhage: a network meta‐analysis. Cochrane Database of Systematic Reviews, (12).
Liu, C. N., Yu, F. B., Xu, Y. Z., Li, J. S., Guan, Z. H., Sun, M. N., & Chen, D. J. (2021). Prevalence and risk factors of severe postpartum hemorrhage: a retrospective cohort study. BMC pregnancy and childbirth, 21(1), 332.
Ministry of Health of the Republic of Indonesia. (2023). Profil Kesehatan Indonesia Tahun 2023. Retrieved from: https://www.kemkes.go.id/resources/download/pusdatin/profil-kesehatan-indonesia/Profil-Kesehatan-Indonesia-2023.pdf
Putri, N. R., & Megasari, A. L. (2022). Uterotonic Use in the Active Management of Third Stage of Labor (AMTSL): Systematic Review. PLACENTUM: Jurnal Ilmiah Kesehatan Dan Aplikasinya, 10(1), 53.
Somanathan, R., Balu, M., Jacob, E., & Illickal, S. M. (2021). A randomised controlled study for the prevention of post-partum haemorrhage with oxytocin plus methyl ergometrine versus oxytocin alone in the third stage of labour. Int J Reprod Contracept Obstet Gynecol, 10(5), 1906-13.
Srinivasan, S. U., & Swarnamukhi, P. (2021). Role of methylergometrine versus oxytocin in the active management of third stage of labour: a randomised control trial. International Journal of Reproduction, Contraception, Obstetrics and Gynecology, 10(10), 3732-3737.
Utami, R. R., & Rahayuningsih, F. B. (2025). Faktor Risiko Terjadinya Perdarahan Pascapersalinan di RSUD Dr. Moewardi Surakarta. Retrieved from: https://journal.universitaspahlawan.ac.id/index.php/prepotif/article/view/40342
Westhoff, G., Cotter, A. M., & Tolosa, J. E. (2013). Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage. Cochrane Database of Systematic Reviews, (10).
Wiciak, H., Strózik, M., & Smereka, J. (2025). Uterotonic Drugs in Prevention and Management in Postpartum Haemorrhage in Prehospital Deliveries—A Systematic Review. In Healthcare (Vol. 13, No. 9, p. 976). MDPI.
World Health Organization. (2020). WHO recommendation on routes of oxytocin administration for the prevention of postpartum haemorrhage after vaginal birth. Retrieved from: https://www.who.int/publications/i/item/9789240013926
World Health Organization. (2025). Trends in maternal mortality 2000 to 2023: estimates by WHO, UNICEF, UNFPA, World Bank Group and UNDESA/Population Division. Retrieved from: https://www.who.int/publications/i/item/9789240108462
Wormer, K. C., Jamil, R. T., & Bryant, S. B. (2024). Postpartum hemorrhage. In StatPearls [internet]. StatPearls Publishing.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 THE JOURNAL OF Mother and Child Health Concerns

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.









